Zafiris J. Daskalakis, MD, PhD

  • 6Articles
  • 50.3KReads
  • 2002–2023Active
  • 28Collaborators
  • 187Citations

About

Zafiris J. Daskalakis, MD, PhD, is affiliated with the Department of Psychiatry at the University of California San Diego. From 2002 to 2023, Daskalakis has published extensively on topics including major depressive disorder, suicide, electroconvulsive therapy, and schizophrenia/schizoaffective disorders. His work covers clinical interventions such as repetitive transcranial magnetic stimulation, continuation magnetic seizure therapy, and antipsychotic treatment in first-episode schizophrenia. He has frequently collaborated with co-authors Daniel M. Blumberger, Benoit H. Mulsant, Cory R. Weissman, Jonathan Downar, and Paul B. Fitzgerald.

Publications

JCP
rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies
Commentary

rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies

April 26, 2023

The authors argue that insurance companies’ prior authorization process overly restricts access to rTMS, which has proven effectiveness for TRD.
, , , et al
JCP
Meta-Analysis

Effect of rTMS on Suicidal Ideation in Treatment-Resistant Depression

January 18, 2022

Repetitive magnetic transcranial stimulation (rTMS) has been established as an efficacious treatment for MDD. This meta-analysis looked at its effects on suicidal ideation in depressed patients across the lifespan.
, , , et al
JCP
Original Research

Continuation MST for Treatment-Resistant Depression

October 19, 2021

Magnetic seizure therapy (MST) has shown promise as an alternative to electroconvulsive therapy for acute treatment-resistant depression (TRD). This study examines the efficacy of MST as a continuation treatment...
, , , et al
JCP
Original Research

Does rTMS Decrease Suicidal Ideation?

April 17, 2018

Read a study on the effects of rTMS on suicidal ideation in patients with treatment-resistant major depression (TRD).
, , , et al
JCP
Original Research

ECT for Schizophrenia

April 26, 2017

ECT is effective in patients with schizophrenia who do not respond to clozapine or cannot take it due to adverse effects. This study, conducted in a large sample using...
, ,
JCP
Original Research

Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade

November 1, 2002

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe